 One of argenxs main competitors, Immunovant, suffered clinical setbacks this year and these setbacks have further solidified efgartigimods potential best-in-class position. argenx to become a commercial-stage company by late-2021 with expected efgartigimod approval for generalized myasthenia gravis. 